Dr. Rafi Kabarriti
Claim this profileMontefiore Medical Center - Moses Campus
Studies Head and Neck Cancers
Studies Squamous Cell Carcinoma
7 reported clinical trials
18 drugs studied
Area of expertise
1Head And Neck Cancers
Stage III
p16 negative
p16 positive
2Squamous Cell Carcinoma
Stage III
Stage IV
p16 negative
Affiliated Hospitals
Clinical Trials Rafi Kabarriti is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
More about Rafi Kabarriti
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rafi Kabarriti has experience with
- Cisplatin
- Intensity-Modulated Radiation Therapy
- Capecitabine
- Fluorouracil
- Mitomycin
- Nivolumab
Breakdown of trials Rafi Kabarriti has run
Head and Neck Cancers
Squamous Cell Carcinoma
Throat Cancer
Oropharyngeal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rafi Kabarriti specialize in?
Rafi Kabarriti focuses on Head and Neck Cancers and Squamous Cell Carcinoma. In particular, much of their work with Head and Neck Cancers has involved Stage III patients, or patients who are p16 negative.
Is Rafi Kabarriti currently recruiting for clinical trials?
Yes, Rafi Kabarriti is currently recruiting for 4 clinical trials in Bronx New York. If you're interested in participating, you should apply.
Are there any treatments that Rafi Kabarriti has studied deeply?
Yes, Rafi Kabarriti has studied treatments such as Cisplatin, Intensity-Modulated Radiation Therapy, Capecitabine.
What is the best way to schedule an appointment with Rafi Kabarriti?
Apply for one of the trials that Rafi Kabarriti is conducting.
What is the office address of Rafi Kabarriti?
The office of Rafi Kabarriti is located at: Montefiore Medical Center - Moses Campus, Bronx, New York 10467 United States. This is the address for their practice at the Montefiore Medical Center - Moses Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.